ADMA BIOLOGICS, INC. Operating Lease Liability
ADMA BIOLOGICS, INC. (ADMA) had Operating Lease Liability of $7.30 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability $7.30M.
- 2025-12-31: Operating Lease, Liability $7.70M.
- 2021-09-30: Operating Lease, Liability $7.40M.
- 2021-06-30: Operating Lease, Liability $7.50M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $7.30M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $7.70M 10-Q · filed 2026-08-05 | |
| 2021-09-30 | $7.40M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $7.50M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $6.70M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $4.70M 10-Q · filed 2021-11-10 | |
| 2020-09-30 | $3.10M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $3.10M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $4.70M 10-Q · filed 2021-05-12 | $1.83M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.50M 10-K · filed 2021-03-25 | $1.30M 10-K · filed 2020-03-13 |
| 2019-09-30 | $1.59M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $1.64M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $1.67M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |